Cocrystal Pharma announced that the U.S. Food and Drug Administration has granted Fast Track designation to its oral antiviral candidate CDI‑988, a direct‑acting protease inhibitor that targets a highly conserved region of the 3CL viral protease. The designation is intended to expedite the development and review of drugs for serious conditions with unmet medical needs, and it allows the company to engage in more frequent FDA communication, pursue rolling review of a New Drug Application, and potentially qualify for Priority Review.
CDI‑988 is being evaluated in a Phase 1b human challenge study at Emory University School of Medicine, where subjects are dosed to assess the compound’s ability to prevent and treat norovirus infections. The study, which began dosing the first subjects in March 2026, is a critical step toward demonstrating clinical efficacy in a tightly controlled setting.
The Fast Track designation underscores the urgency of developing a treatment for norovirus, a pathogen that causes an estimated 685 million cases worldwide each year and generates roughly $60 billion in economic impact. With no approved antiviral therapies or vaccines, CDI‑988 represents a first‑in‑class opportunity to address a substantial unmet medical need.
Sam Lee, Ph.D., President and co‑CEO of Cocrystal Pharma, said the designation “marks a significant milestone for Cocrystal and a critical step toward helping patients with norovirus.” He added that the Fast Track status “further validates using our unique structure‑based drug discovery technology to design pan‑viral antivirals that are effective new treatment options.”
The company highlighted that CDI‑988 has particular potential in high‑risk environments such as hospitals, nursing homes, cruise ships, schools and military facilities. The human challenge model is designed to provide proof‑of‑concept for the compound in a controlled setting, which could accelerate regulatory progress.
Market participants reacted strongly to the announcement. Analysts noted that the Fast Track designation could shorten the regulatory timeline and increase the likelihood of market approval, thereby expanding Cocrystal’s potential revenue streams. The designation also signals confidence in the company’s proprietary platform and its ability to address a global health priority.
Cocrystal Pharma’s stock experienced a notable increase following the announcement, reflecting investor enthusiasm for the regulatory milestone and the company’s progress in its drug development pipeline.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.